Sun recalls more product, this time from plant in Hungary

FDA sign

Sun Pharmaceutical, which has been dealing with FDA concerns over plants in India, is now recalling more than 12,000 bottles of a beta blocker made at a plant in Hungary.  

According to the most recent FDA Enforcement Report, Sun is recalling 12,109 bottles of Carvedilol tablets manufactured at its Alkaloida Chemical site in Tiszavasvari, Hungary.

The voluntary recall, which has just been classified by the FDA, began in June. The four recalls were initiated after the products failed impurities and degradation testing, the report says.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

In June, Sun also began a recall of 16,085 bottles of the antidepressant bupropion hydrochloride extended-release tablets manufactured at its Halol, India, plant because they failed specifications for dissolution.

The plant is one of Sun's primary facilities for providing products to the U.S., so Sun saw sales slip after the FDA cited its Halol plant with a Form 483 in 2014. The agency issued a warning letter to the plant last December for a host of quality and data integrity issues, and the drugmaker recalled a number of products as a result.

More recently, Sun’s manufacturing shortcomings surfaced in the U.S., this time at a plant in Philadelphia which it sold in June to Frontida BioPharm. The FDA hit the plant with a warning letter last month. Frontida has said that Sun was upfront with it about the FDA’s concerns when it bought the plant and that Sun has agreed to work with Frontida to get the facility into shape.

Frontida, a newly formed CDMO, is an affiliate company to Frontage Laboratories, a long-standing CRO in Pennsylvania, New Jersey and China that is controlled by Chinese CRO Hangzhou Tigermed.

The warning letter for the Philly plant said its quality unit “knowingly released 27 lots of various strengths of clonidine HCl tablets in March 2015,” despite evidence that the active pharmaceutical ingredient to make them “was potentially contaminated.”

- access the recalls here

Related Articles: 
Sun Pharma nagged by Halol plant recall
Frontida says it had full knowledge of FDA issues of Sun's Mutual plant in Philly 
Frontida gets warning letter for plant it just bought from Sun

Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.